Therapeutic implications of corticosteroid formulations

Vloten, Wa Van

doi:10.3109/09546639009089038

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also the composition of the vehicle has a substantial influence on the potency of topical preparations [14][15][16], Since the introduction of corticosteroids, chemical engineering has provided a series of optimized steroid molecules for topical prep arations [16,20], Mometasone furoate is a recently introduced synthetic corticosteroid in which the steroid nucleus is a 16-methyl analogue of beclomethasone with a 21 -chloro group and a novel (2') furoate 17-ester. Mom etasone furoate is strongly lipophilic, which seems to be associated with a high penetration rate [20].…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Bjerring¹

1993

Skin Pharmacol Physiol

View full text Add to dashboard Cite

The bioactivity of a novel topical glucocorticosteroid, mometasone furoate 0.1 % fatty cream was compared with betamethasone dipropionate 0.05% cream and betametasone valerate 0.1% cream. An ultraviolet light (UV-B)-induced inflammation assay in humans was used, and the combined effect of a single, open application of the corticosteroids was evaluated. Reduction of UV-B induced inflammation was monitored by laser Doppler blood flowmetry, clinical skin scoring and skin reflectance spectrophotometry. Skin scoring and reflectance spectrophotometry were found unsuitable because one of the cream vehicles contained titanium dioxide which shielded skin erythema. Laser Doppler blood flowmetry showed that mometasone furoate 0.1 % fatty cream was more than twofold better in reducing UV-B-induced inflammation than betamethasone dipropionate 0.05% cream and betametasone valerate 0.1 % cream, and that the effect was sustained for at least 24 h after a single application.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Bjerring¹

1993

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…Both MPA and HCB were evaluated using a lotion-type formulation, which is considered to be the optimal vehicle for acute dermatitis such as sunburn. 14 The size and distance between test sites were adequate for visual and subjective assessment. The primary outcome measures were based on clinically relevant signs and symptoms.…”

Section: Discussionmentioning

confidence: 98%

“…Skin areas were irradiated with 3 MED, and treatment was applied 6 h after irradiation in all subjects. Both MPA and HCB were evaluated using a lotion‐type formulation, which is considered to be the optimal vehicle for acute dermatitis such as sunburn 14 . The size and distance between test sites were adequate for visual and subjective assessment.…”

Section: Discussionmentioning

confidence: 99%

A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers

Duteil

Queille‐Roussel

Lorenz³

et al. 2002

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Topical glucocorticosteroids are frequently used for the treatment of sunburn despite the scarcity of randomized, double-blind controlled trials to support this indication. This randomized, intra-individually controlled trial compared the efficacy and safety of two topical glucocorticosteroids, 0.1% methylprednisolone aceponate milk (MPA) and 0.1% hydrocortisone 17-butyrate emulsion (HCB), for treatment of sunburn in 24 healthy volunteers of skin type III. After irradiation of the skin by simulated sunlight, treatments were blinded and randomly allocated to 36 cm2 test areas on both sides of the spine. Volunteers were treated twice daily for 7 days and assessed daily with 1-day follow-up. The untreated area was not blinded. Primary efficacy measures were sum score and sunburn reaction based on erythema, oedema, burning and itching. Secondary efficacy measures were physician's global assessment, individual signs/symptoms, colorimetry, dermatological improvement, and time to healing. Intra-individual comparisons were made. Differences in sum score were apparent on days 3-4 and significant on days 4-5 for corticosteroids compared with nontreatment. Treated areas had significantly lower sunburn reaction than untreated areas (P = 0.1% and P = 0.5% for MPA and HCB, respectively). Differences between treatments were not significant. Secondary efficacy measures were in line with these findings. None of the three adverse events reported were considered to be related to treatment. We conclude that MPA and HCB are safe and effective in the treatment of sunburn.

show abstract

Methylprednisolone Aceponate

Haria¹,

Balfour²

1995

Clin. Immunother.

View full text Add to dashboard Cite

Therapeutic implications of corticosteroid formulations

Cited by 4 publications

References 16 publications

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers

Methylprednisolone Aceponate

Contact Info

Product

Resources

About